23rd Street station (IND Eighth Avenue Line)

TScan Therapeutics Presents Preclinical Data for Solid Tumor Program at the 37th Society for Immunotherapy of Cancer Annual Meeting

Retrieved on: 
Friday, November 11, 2022
Clinical trial, HLA, Observation, Mouse, Result, Melanoma, Society for Immunotherapy of Cancer, Annual report, Society, SITC, MAGE-A1, Cancer, Antigen, PRAME, Private Securities Litigation Reform Act, TCR, Securities Exchange Act of 1934, Therapy, Analysis, Immunotherapy, Collection, Peptide, GLOBE, Research, Financial condition report, 23rd Street station (IND Eighth Avenue Line), Patient, Annual general meeting, Safety, COVID-19, Head, Growth, Nasdaq, Epitope, IND, Neoplasm, Medical imaging, Pharmaceutical industry, Vaccine, Company

WALTHAM, Mass., Nov. 11, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the presentation of two posters at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting.

Key Points: 
  • We are solving this problem by building a diverse collection of therapeutic TCRs to enable customized multiplexed TCR-T therapy.
  • The discovery of PRAME-specific TCRs and the observation that they synergize with our MAGE-A1-specific TCRs marks the next step in our solid tumor program.
  • We continue to focus on growing our ImmunoBank and pursuing our clinical and regulatory strategy to bring customized therapies to patients with a broad range of solid tumor malignancies.
  • Discovery of PRAME-specific TCR-T cell therapy candidates for the treatment of solid tumors, presented by Mollie Jurewicz, Ph.D.

Imvax Presents Preclinical Data at SITC 2022 Supporting Mechanism of Action and Anti-tumor Activity of its Immunotherapy Platform Across Multiple Tumor Types

Retrieved on: 
Thursday, November 10, 2022
Oncology, Health, Clinical Trials, Research, Science, Biotechnology, ICD, B cell, Immunotherapy, Neoplasm, GBM, Technology, Mouse, Glioblastoma, Doctor of Philosophy, Immunogenic cell death, Synthetic control method, Survival, SITC, Lymph, Liver, Society for Immunotherapy of Cancer, 23rd Street station (IND Eighth Avenue Line), Cell death, Pharmaceutical industry, Vaccine

These new data provide further evidence of the unique mechanism of our immunotherapy platform and its potential applicability in a wide variety of tumor types beyond glioblastoma, where we have compelling clinical data, said Mark A. Exley, Ph.D., Chief Scientific Officer.

Key Points: 
  • These new data provide further evidence of the unique mechanism of our immunotherapy platform and its potential applicability in a wide variety of tumor types beyond glioblastoma, where we have compelling clinical data, said Mark A. Exley, Ph.D., Chief Scientific Officer.
  • These data support our lead program, IGV-001, which combines personalized, autologous, whole-tumor derived cells with an antisense oligonucleotide in implantable biodiffusion chambers.
  • These data suggest a potential mechanism of action of IGV-001 in GBM via ICD stimulation of an antitumor immune response.
  • The second poster presentation on November 11, 2022, provides evidence for the broad, systemic, and durable antitumor activity of Imvaxs platform.

TScan Therapeutics Secures Convertible Debt Facility for up to $60 Million with K2 HealthVentures

Retrieved on: 
Monday, September 12, 2022
Securities Exchange Act of 1934, Safety, COVID-19, Lymphatic system, IND, HLA, Company, Growth, Private Securities Litigation Reform Act, Therapy, U.S. Securities and Exchange Commission, Patient, TCR, Hand, Clinical trial, Cancer, Prime rate, Hematopoietic stem cell transplantation, CEO, Analysis, Financial condition report, Result, Solution, Goal, Nasdaq, Annual report, Research, Security (finance), 23rd Street station (IND Eighth Avenue Line), GLOBE, Pharmaceutical industry

WALTHAM, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that it has entered into a debt financing facility for up to $60 million with K2 HealthVentures (K2HV), a healthcare-focused specialty finance company.  

Key Points: 
  • TScan drew $30 million from K2HV upon closing of the loan agreement.
  • The first tranche of the loan is convertible at the option of K2HV into common shares of TScan at a conversion price of approximately $4.785 per share.
  • K2 HealthVentures is an alternative investment firm focused on providing flexible, long-term financing solutions to innovative private and public companies in the life sciences and healthcare industries.
  • Except as required by law, TScan explicitly disclaims any obligation to update any forward-looking statements.

CytomX Therapeutics Provides Strategic Update

Retrieved on: 
Wednesday, July 13, 2022
Epithelial cell adhesion molecule, Clinical trial, 23rd Street station (IND Eighth Avenue Line), Safety, Biotechnology, Bi-specific T-cell engager, Program, EGFR, Therapeutic index, Nivolumab, IND, New Drug Application, Therapy, AbbVie, IFN, Company, LinkedIn, TCB, Risk, Organization, United, Conditional, ADC, Patient, SAN, Triple-negative breast cancer, Ipilimumab, GLOBE, COVID-19, Director, Conjugation, Nasdaq, Neoplasm, CD71, Amgen, CD166, Cancer, Research, Twitter, Board, Workforce, CD3, Partnership, Bristol Myers Squibb, Pharmaceutical industry, Vaccine, Fine chemical, Astellas Pharma

SOUTH SAN FRANCISCO, Calif., July 13, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced plans to focus on its emerging pre-clinical and early clinical pipeline and to realign its capital resources to drive these efforts.

Key Points: 
  • With the Probody therapeutic platform, CytomX has pioneered a new and strategic field of biologics drug discovery and development.
  • CytomX has established strategic collaborations with multiple leaders in oncology, including AbbVie, Amgen, Astellas, and Bristol Myers Squibb.
  • CytomX does not undertake and specifically disclaims any obligation to update any forward-looking statements, whether as a result of any new information, future events, changed circumstances or otherwise.
  • Probody is a U.S. registered trademark of CytomX Therapeutics, Inc.

TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-101 for the Treatment of Hematologic Malignancies

Retrieved on: 
Tuesday, May 31, 2022
Risk, Company, Blood, Private Securities Litigation Reform Act, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, GMP, Nasdaq, Transplant, 23rd Street station (IND Eighth Avenue Line), Patient, Financial condition report, Result, Kinetics, Therapy, Clinical trial, COVID-19, Lymphatic system, HLA, Research, FDA, IND, TCR, Securities Exchange Act of 1934, Antigen, Leukemia, Safety, HCT, Hematopoietic stem cell transplantation, SEC, Cancer, Analysis, GLOBE, Vaccine, Pharmaceutical industry

The target of TSC-101 is the minor histocompatibility antigen HA-2, which is a lineage-specific antigen expressed on blood cells.

Key Points: 
  • The target of TSC-101 is the minor histocompatibility antigen HA-2, which is a lineage-specific antigen expressed on blood cells.
  • TScan believes that TSC-101 is the first clinical program to target the HA-2 antigen.
  • As previously announced, TScans IND for TSC-100, which targets the minor histocompatibility antigen HA-1, was cleared by the FDA in January 2022.
  • Except as required by law, TScan explicitly disclaims any obligation to update any forward-looking statements.

Homology Medicines Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights

Retrieved on: 
Wednesday, March 23, 2022
Private Securities Litigation Reform Act, PKU, Liver function tests, Phenix, JumpStart, Phenylketonuria, Liver, Research, SEC, European Medicines Agency, Year-ending, PNH, Glycogen storage disease, Time, Nasdaq, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, GLOBE, Program, GMP, Annual report, Disease, Gene, Chairperson, MLD, Central nervous system, Enzyme replacement therapy, CMC, Conference, Gene editing, Hunter syndrome, Paroxysmal nocturnal hemoglobinuria, ATMP, EMA, Letter, Therapy, Investment, Clinical trial, Board, Ownership, CNS, Failure, Pfizer, FDA, OXB, Patient, Antibody, Partnership, Company, ERT, Organization, Classification, Collaboration, Compliance, AAV, Novartis, Food, Safety, COVID-19, Pharmaceutical industry, Management, Vaccine, Access, 23rd Street station (IND Eighth Avenue Line), IND

BEDFORD, Mass., March 23, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today financial results for the fourth quarter and full year ended December 31, 2021, and highlighted recent accomplishments.

Key Points: 
  • The Company has already incorporated this regimen into its pheEDIT gene editing trial for adults with PKU.
  • As a result, the Company now expects to provide a program update when the path forward is established with FDA.
  • As of December 31, 2021, Homology had approximately $155.9 million in cash, cash equivalents and short-term investments.
  • Homology Medicines, Inc. is a clinical-stage genetic medicines company dedicated to transforming the lives of patients suffering from rare diseases by addressing the underlying cause of the disease.

Foghorn Therapeutics Provides Full Year 2021 Corporate Update and 2022 Outlook

Retrieved on: 
Thursday, March 10, 2022
Nasdaq, Mum, Clinical trial, Â, Choroid, Cost sharing, Chromatin, Ciliary body, BAF, Company, Ligament, Research, U.S. Securities and Exchange Commission, Gottschalk, BRD9, Iris, Cell, Sarcoma, AML, Cancer, 23rd Street station (IND Eighth Avenue Line), Mutation, Economics, Synovial sarcoma, MDS, Adult, Bone marrow, Acute leukemia, ARID1A, GLOBE, BRM, Gene expression, Acute myeloid leukemia, Security (finance), ATPase, Blood, Myelodysplastic syndrome, BRG1, Therapy, Lilly, Neoplasm, Program, ARID1B, Forward-looking statement, NSCLC, Protein, Fine chemical, Cryptocurrency, Pharmaceutical industry, Vaccine, Dietary supplement, Foghorn

CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, today provided a corporate update including the Company’s 2021 key achievements and 2022 strategic priorities in conjunction with its 10-K filing for the year ended December 31, 2021. With an initial focus in oncology, Foghorn’s Gene Traffic Control® Platform and resulting broad pipeline has the potential to transform the lives of people suffering from a wide spectrum of diseases.

Key Points: 
  • In January 2022, Foghorn added Dannette Daniels as our Vice President, Protein Degrader Platform, continuing our investment in and expansion of our protein degrader capabilities.
  • In December 2021, Foghorn and Lilly announced a strategic collaboration for novel oncology targets using Foghorns proprietary Gene Traffic Control Platform.
  • In December 2021, Foghorn and Loxo Oncology at Lilly entered into a strategic collaboration for novel oncology targets.
  • Foghorn Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system.

Dyne Therapeutics Highlights Preclinical Data and Clinical Development Plans for DMD and DM1 Programs at Inaugural R&D Day

Retrieved on: 
Wednesday, October 13, 2021
People, Facioscapulohumeral muscular dystrophy, Form 10-Q, Professor, Program, Terminology, Duchenne muscular dystrophy, Private Securities Litigation Reform Act, Nasdaq, LinkedIn, IND, Myopathy, DMD, Intention, FSHD, Congress, Security (finance), Adult, MAD, DM1, SEC, MPH, Therapy, Neurology, IPO, Disease, Degenerative disease, Neuromuscular disease, Patient, Clinical trial, Development, Pediatrics, GLOBE, Science, Research, Securities and Exchange Commission (Philippines), R, Company, University, National Institutes of Health Clinical Center, Review, Twitter, Safety, DYN, Doctor of Philosophy, 23rd Street station (IND Eighth Avenue Line), Clinical, Associate, COVID-19, Pharmaceutical industry

WALTHAM, Mass., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, hosts its first Research and Development Day today focused on the Company’s co-lead development programs for rare muscle diseases, Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). “The Muscle to Move to the Clinic” live virtual event (8:00-10:30 a.m. ET) as well as the replay and slide presentation are available at https://investors.dyne-tx.com/events/event-details/dyne-rd-day.

Key Points: 
  • For its DMD program, Dyne intends to initiate a global, placebo-controlled, multiple-ascending dose (MAD) clinical trial to evaluate DYNE-251 in patients with mutations amenable to exon 51 skipping.
  • The Company also intends to initiate a global, placebo-controlled, MAD clinical trial evaluating DYNE-101 in adult patients with DM1.
  • Dyne may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements.
  • However, while Dyne may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

Tango Therapeutics Announces Presentation of Preclinical Data on Lead Program and Discovery Platform in Five Abstracts Accepted at AACR-NCI-EORTC 2021

Retrieved on: 
Thursday, September 30, 2021
Biotechnology, Health, Stem Cells, Clinical Trials, Oncology, Patent, Goal, Therapy, Clinical trial, Cancer, 2021 Essex County Council election, Risk, Conference, NASDAQ, Precision medicine, Patient, AACR, MTA, Company, Terminology, 23rd Street station (IND Eighth Avenue Line), COVID-19, Technology, IND, Forward-looking statement, Safety, Intellectual property, PRMT5, Time, MTAP, SEC, Pharmaceutical industry

The preclinical data being presented today highlight the potential applicability of synthetic lethal drug targeting across a range of cancer types.

Key Points: 
  • The preclinical data being presented today highlight the potential applicability of synthetic lethal drug targeting across a range of cancer types.
  • We look forward to leveraging these data to inform our planned clinical development program.
  • Dr. Weber will also be co-chairing an Educational session titled Exploiting Synthetic Lethality on October 7, 2021 at 10:00 AM ET.
  • These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Tango and its management are inherently uncertain.